(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 March 2022 (24.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/061149 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 9/14* (2006.01)
A61K 31/501 (2006.01) *A61P 1/00* (2006.01)
A61P 17/06 (2006.01)

(21) International Application Number:
PCT/US2021/050928

(22) International Filing Date:
17 September 2021 (17.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/080,030 18 September 2020 (18.09.2020) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: **KESTUR, Umesh**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **BADAWY, Sherif Ibrahim Farag**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **KOEHLER-KING, Dory**; c/o Bend Research, Inc., 1201 N. Wall Street, Suite 200, Bend, Oregon 97703 (US). **SATHER, Craig Allen**; c/o Bend Research, Inc., 1201 N. Wall Street, Suite 200, Bend, Oregon 97703 (US). **KYBURZ, Kyle**; c/o Bend Research, Inc., 1201 N. Wall Street, Suite 200, Bend, Oregon 97703 (US).

(74) Agent: **ROBBINS, Jennifer L.** et al.; (c/o Patent Docketing), Covington & Burling LLP, One CityCenter, 850 Tenth Street, NW, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES

(57) Abstract: A swellable core dosage form comprises a dispersion of amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

WO 2022/061149 A1